Cite

HARVARD Citation

    Verzoni, E. et al. (n.d.). 882PPotent natural killer (NK) and myeloid blood cell remodeling by cabozantinib (Cabo) in pre-treated metastatic renal cell carcinoma (mRCC) patients (pts). Annals of oncology. p. . [Online]. 
  
Back to record